Article Figures & Data
Figures
- FIGURE 1.
Multiple variable-sized, dura-based enhancing lesions exhibit somatostatin receptor positivity on 68Ga-DOTATATE PET/CT. One tracer-avid bone marrow focus on right frontal bone is concerning for meningioma transosseous infiltration (arrows). Maximum-intensity projection exhibits extensive tumor burden of recurrent meningioma. Shown are CE MR image (A), 68Ga-DOTATATE PET image (B), low-dose CT image (C), PET/MR image (D), PET/CT image (E), and PET maximum-intensity projection (F).
- FIGURE 2.
68Ga-DOTATATE PET/CT/MRI series, adapted for radiation therapy planning for proton bean therapy, showed enhancing lesions centered at right temporal craniectomy site, indicating residual tumor after subtotal resection. Three-year follow-up CE MRI showed deceased size of tumor, indicating favorable response to radiation therapy. F/u = follow-up.
- FIGURE 3.
In 68Ga-DOTATATE PET/CT/MRI series, CE MRI demonstrated enhancing focus at parietal vertex, which exhibited PET avidity (red arrows). PET/CT was able to identify another PET-avid focus at parasagittal left frontal region, indicative of recurrence (green arrows).
Tables
Patient no. Sex WHO grade Age (y) Initial location Onset Treatment history PET/CT time (y) PET/CT findings Follow-up therapy Outcome 1 F 1 69 Right frontal 2005 Craniotomy × 3, CyberKnife embolization 12 Positive Bevacizumab, octreotide Died 2 F 2 82 Right sphenoid 2016 Craniotomy × 2 1 Positive × 2 Proton beam therapy Survived 3 M 2 72 Bifrontal 2009 Craniotomy × 3, radiation therapy 8 Positive Octreotide Died 4 M 2 59 Left skull base 2008 γ-knife 10 Positive Octreotide Died 5 M 2 77 Bifrontal 2012 Radiosurgery, craniotomy × 2 7 Positive Octreotide, bevacizumab Died 6 M 2 72 Left frontoparietal 2015 Craniotomy × 1, radiation therapy 3 Positive Proton beam therapy Survived 7 F 3 47 Right frontal 2008 Craniotomy × 1 12 Negative × 2 Surveillance Survived 8 F 1 68 Right skull base 2021 Partial resection 1 Positive Radiation therapy Survived
